Lyme Disease Vaccine Crosses European Review Threshold, but Statistical Questions Remain Behind 70% Protection

A Lyme disease vaccine has moved one step closer to the European market. The European Medicines Agency (EMA) has confirmed that the marketing authorization application submitted by Pfizer and Valneva for PF-07307405, also known as VLA15, is complete and can proceed to formal review. Crossing this administrative threshold means the vaccine candidate will undergo a comprehensive assessment of its efficacy, safety, and quality, not that it has received preliminary approval.

VLA15 is a hexavalent vaccine targeting outer surface protein A (OspA) of the Lyme disease spirochete and is intended to cover six OspA serotypes commonly found in North America and Europe. Its design aims to induce antibodies in vaccinated individuals that block transmission after a tick bite while the pathogen is still inside the tick.

The marketing authorization application is based primarily on the randomized, placebo-controlled, observer-blinded Phase 3 VALOR trial. Participants were aged 5 years or older and received a three-dose primary vaccination series followed by a booster dose approximately 12 months later. Pfizer and Valneva said no new vaccine-related safety concerns were identified among the 9,437 participants included in the primary analysis.

The efficacy figures require more nuanced interpretation. Beginning 28 days after the fourth dose, the prespecified primary analysis estimated vaccine efficacy at 73.2%, but the 95% confidence interval was quite wide, ranging from 15.8% to 93.5%. Because the lower bound did not exceed the trial’s prespecified 20% threshold, the primary analysis did not meet the statistical criterion. The companies believe that fewer Lyme disease cases occurred than expected, which was one reason for the increased uncertainty.

Another analysis, also prespecified and calculated beginning on the first day after the fourth dose, estimated efficacy at 74.8%, with a 95% confidence interval of 21.7% to 93.9%; its lower bound crossed the 20% threshold. The point estimates of efficacy were similar in the two analyses, yet their statistical conclusions differed, indicating that the number of cases, the starting point for observation, and the width of the intervals will be important issues as regulators assess the strength of the evidence.

There are also differing figures for the trial’s size. The ClinicalTrials.gov registry records actual enrollment of 12,546 participants and states that the analysis population of approximately 9,400 excluded eight trial sites that were terminated because of quality issues. This does not necessarily invalidate the efficacy results, but the EMA must still examine how data were excluded, how cases were adjudicated, and how robust the results are before determining whether the existing evidence is sufficient to support widespread vaccination.

Next, the EMA’s Committee for Medicinal Products for Human Use will assess the vaccine’s benefits, risks, and manufacturing quality. The active review period can last up to 210 days, excluding clock-stop periods while awaiting additional information from the applicants. After the committee issues its opinion, the final decision on marketing authorization will still be made by the European Commission. In other words, VLA15 has entered a critical stage of review, but whether its efficacy estimate of around 70% can overcome questions about statistics and data quality is the central issue the review must resolve.